Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02863835
Other study ID # 16/LO/0198
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 2016
Est. completion date June 2017

Study information

Verified date May 2018
Source Guy's and St Thomas' NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Electrical impedance tomography (EIT) is non-invasive and provides functional imaging of the lung and it could be a useful tool to diagnose chronic lung allograft dysfunction (CLAD) and specially Bronchiolitis Obliterans Syndrome (BOS). Hence, for this study, the investigators aim to show that EIT would provide an accurate diagnostic CLAD with an ability to to distinguish BOS from Restrictive Allograft Syndrome (RAS) and to stage BOS accurately when compared to FEV1 the current gold standard. The investigators are also aiming to provide physiological data in lung transplant recipients with chronic rejection.


Description:

Lung transplantation is the only treatment option available for patients affected by end-stage lung diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis or idiopathic pulmonary fibrosis, not responding to maximal medical therapy. Despite the advance in the surgical techniques, immunosuppression treatment and prevention of acute cellular rejection episodes as well as opportunistic infections, the long terms outcomes following lung transplant remain unsatisfactory. Chronic lung allograft dysfunction (CLAD) is the first cause of long term mortality in lung transplant recipients responsible of 5 years mortality post-surgery of 50%. CLAD can lead to chronic respiratory failure and can presents in two different phenotypes: Restrictive forms of CLAD were all lung volumes are decreased (commonly called RAS, Restrictive Allograft Syndrome) that has been recently associated with antibodies mediated rejection. A more common form of obstructive CLAD has been identified as the well-known and defined Bronchiolitis Obliterans Syndrome (BOS). In patients with BOS, the progressive obliteration and a narrowing of the distal airways result in breathlessness, airflow obstruction and air trapping.

Currently, Forced Expiratory Volume at 1 second (FEV1) measurement is the gold standard to assess BOS severity. This test is non invasive and easily performed at bedside. Thus, it only gives a broad idea of the regional consequences of BOS as may be influenced by large airway obstructions. Chest computed tomography (CT) gives more detailed imaging of the regional consequences of BOS but is time-consuming and expose patients to radiations. Others imaging techniques such as ventilation/perfusion scintigraphy have been studied but cannot be performed at bedside.

As to date there is no curative treatment for BOS, preventive treatments such as long term azithromycin, bronchodilators, inhaled steroids or plasmapheresis have to be started at early stage of the disease to improve outcomes for the recipients Electrical impedance tomography (EIT) is a new technology that involves wearing a belt of sensors around the chest that provides information on how well the lungs are being filled with air by the ventilator. It allows the assessment of these differences, which previously required the use of invasive equipment to obtain. Information is gained by repeatedly injecting small alternating electric currents (usually 5 mA) at high frequency of 50 - 80 kHz through a system of skin electrodes (usually 16) applied circumferentially around the thorax in a single plane between the 4th and 6th intercostal space. While an adjacent pair of electrodes 'injects' the current ('adjacent drive configuration'), all the remaining adjacent passive electrode pairs measure the differences in electric potential. A resistivity (impedance) image is reconstructed from this data by a mathematical algorithm using a two dimensional model and a simplified shape to represent the thoracic cross-section.

The resulting image possesses a high temporal and functional resolution making it possible to monitor dynamic physiological phenomena (e.g. delay in regional inflation or recruitment) on a breath by breath basis. It is important to realize that the EIT images are based on image reconstruction techniques that require at least one measurement on a well-defined reference state. All quantitative data are related to this reference and can only indirectly quantify (relative) changes in local lung impedance (but not absolute).

EIT can be used in mechanically ventilated patients to assess recruitment and to optimise ventilator settings to reduce risk of iatrogenic ventilator associated lung injury. To date, EIT has never been used in lung transplant recipients.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date June 2017
Est. primary completion date June 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- Bilateral lung transplant recipient

- Time from lung transplantation > 6 months

- A chest CT scan (HRCT) performed as part of their standard care in the last 3 months

- A bronchoscopy with BAL and Biopsies performed as part of their standard care in the last 3 months

- For group with CLAD: a drop in lung function assessed on FEV1 or FVC

- For group without CLAD: an unchanged lung function

Exclusion Criteria:

- Pregnancy

- Body mass index > 40kg/m2

- Significant physical or psychiatric comorbidity that would prevent compliance with trial protocol

- Allergy to salbutamol

- Patient with intra-bronchial or intra-tracheal metallic stent

- Evidence of acute infection or acute cellular rejection.

In addition 10 healthy volunteers will be recruited

Study Design


Related Conditions & MeSH terms


Intervention

Other:
EIT
All participants will have continuous monitoring of EIT whilst self venting
Salbutamol nebulisation and with CPAP
All participants will have continuous monitoring - salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure during this time.

Locations

Country Name City State
United Kingdom Guys and St Thomas NHS Foundation London

Sponsors (2)

Lead Sponsor Collaborator
Guy's and St Thomas' NHS Foundation Trust ADIR Association

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of chronic lung allograft dysfunction in lung transplant recipients identified with EIT Using EIT to diagnose chronic lung allograft dysfunction in lung transplant recipients 1 day
Primary Restrictive and obstructive phenotypes in recipients of lung transplants. Using EIT to distinguish between restrictive and obstructive different phenotypes in recipients of lung transplants 1 day
Secondary Change in EIT results following administration of salbutamol and CPAP Following administration of salbutamol whilst using CPAP taking EITresults to determine if there is a change in the lungs 1 day
Secondary Correlation EIT results and chest-CT results Comparing Lung measurements taken during the EIT test with the CT results of the participants to ascertain if there is any correlation 1 day
Secondary Neural respiratory drive (EMGpara) of lung transplant recipients Comparing lung measurements taken during the EIT test with those taken during neural respiratory drive during the intervention 1 day
Secondary Correlation between EIT and neural respiratory drive results with breathlessness Comparing lung measurements taken during the EIT test with the Neural respiratory drive results taken and the participants breathlessness 1 day
Secondary Correlation of EIT results found in obstructive and restrictive allograft syndrome Comparing the obstructive allograft syndrome EIT results to the restrictive allograft syndrome results. 1 day
See also
  Status Clinical Trial Phase
Completed NCT01807975 - Forced Oscillation Versus Spirometry in Diagnosing Post Pulmonary Transplant Bronchiolitis Obliterans Syndrome N/A
Completed NCT01009619 - Azithromycin in Bronchiolitis Obliterans Syndrome Phase 4
Recruiting NCT04391335 - Novel Pulmonary Function Measures for Diagnosis of Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem-Cell Transplantation in Children
Recruiting NCT05250037 - The Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation (The RV-BOS Study)
Enrolling by invitation NCT04039347 - Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3) Phase 3
Recruiting NCT05413356 - Ruxolitinib for Newly Diagnosed Bronchiolitis Obliterans Syndrome Phase 2
Recruiting NCT00774449 - Characterization of Bronchiolitis-obliterans Syndrome (BOS) Following Lung Transplantation N/A
Recruiting NCT05922761 - BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) Phase 2
Terminated NCT03978637 - Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation Phase 1/Phase 2
Completed NCT02316392 - Imaging and Understanding BOS in Lung Transplantation
Completed NCT00528853 - Correlation of Lung Biopsy, BAL, and High Resolution CT Scan in Lung Transplantation N/A
Recruiting NCT06018766 - LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome. Phase 2
Recruiting NCT02669251 - Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation Phase 1/Phase 2
Recruiting NCT03072849 - Early Detection and Management of Bronchiolitis Obliterans Syndrome Following Pediatric Hematopoietic Stem Cell Transplantation N/A